Literature DB >> 32492490

Delivery routes for faecal microbiota transplants: Available, anticipated and aspired.

Monica Gulati1, Sachin Kumar Singh2, Leander Corrie2, Indu Pal Kaur3, Lipika Chandwani2.   

Abstract

Fecal microbiota transplant (FMT) has seen a historic emergence in last decade with its sojourn recently entering into a chequered path, due to a few reports of infection and subsequent mortality. Though FMT has been extensively reported, there is no comprehensive report on the delivery routes available for this non-pharmacological treatment option. Safety, efficacy and cost of FMT not only depend on the quality of contents but also on the delivery route employed. A number of delivery routes are in use for conducting FMT, which include upper gastrointestinal routes (UGI) i.e. nasogastric/nasojejunal tube, endoscopy, oral capsules and lower gastrointestinal routes (LGI) like retention enema, sigmoidoscopy or colonoscopy. Capsules, both conventional as well as colon targeted have been the most commonly used formulations. Surprisingly, the success rates with conventional gastric delivery capsules and colon targeted capsules were found to be quite similar indicating the sufficiency of the inoculum size to withstand the microbial loss in the gastric milieu. Patient compliance, cost effectiveness, comfort of administration, level of invasiveness, patient's hospital admission, risk of aspiration and infections, multiplicity of administration required, recurrence rate are the main factors that seem to influence the choice for route of administration of physicians. The best route for FMT has not been established yet. Extensive studies are required to understand the interplay of route adopted, type of donor, physical nature of sample (fresh or frozen), patient compliance and cost effectiveness to design an approach for the risk free, convenient and cost-effective administration route for FMT.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Esophagogastroduodenoscopy; Fecal microbiota transplant; Percutaneous endoscopic cecostomy; Transendoscopic enteral tubing (TET)

Mesh:

Substances:

Year:  2020        PMID: 32492490     DOI: 10.1016/j.phrs.2020.104954

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease.

Authors:  Xi-Yue Tan; Yu-Jia Xie; Xing-Long Liu; Xin-Yun Li; Bo Jia
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-26       Impact factor: 2.650

2.  Prevention of Ulcerative Colitis by Autologous Metabolite Transfer from Colitogenic Microbiota Treated with Lipid Nanoparticles Encapsulating an Anti-Inflammatory Drug Candidate.

Authors:  Chunhua Yang; Junsik Sung; Dingpei Long; Zahra Alghoul; Didier Merlin
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

3.  Composition of Human Breast Milk Microbiota and Its Role in Children's Health.

Authors:  Veronica Notarbartolo; Mario Giuffrè; Claudio Montante; Giovanni Corsello; Maurizio Carta
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2022-05-09

4.  Fecal Microbiota Transplantation: Is It Safe?

Authors:  Seon-Young Park; Geom Seog Seo
Journal:  Clin Endosc       Date:  2021-03-30

5.  Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases.

Authors:  Gianluca Ianiro; Michal Punčochář; Nicolai Karcher; Serena Porcari; Federica Armanini; Francesco Asnicar; Francesco Beghini; Aitor Blanco-Míguez; Fabio Cumbo; Paolo Manghi; Federica Pinto; Luca Masucci; Gianluca Quaranta; Silvia De Giorgi; Giusi Desirè Sciumè; Stefano Bibbò; Federica Del Chierico; Lorenza Putignani; Maurizio Sanguinetti; Antonio Gasbarrini; Mireia Valles-Colomer; Giovanni Cammarota; Nicola Segata
Journal:  Nat Med       Date:  2022-09-15       Impact factor: 87.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.